lna-mediated microrna silencing non-human primates 
micrornas mirnas small regulatory rnas important development disease- therefore represent potential new class targets therapeutic intervention despite recent progress silencing mirnas rodents development effective safe approaches sequence-specific antagonism mirnas vivo remains significant scientific therapeutic challenge moreover reports mirna antagonism primates show simple systemic delivery unconjugated pbs formulated locked nucleic acid modified oligonucleotide lna antimir effectively antagonizes liver expressed mir non human primates acute administration intravenous injections mg kg- lna antimir african green monkeys resulted uptake lna antimir cytoplasm primate hepatocytes formation stable heteroduplexes lna-antimir mir accompanied depletion mature mir dose dependent lowering plasma cholesterol efficient silencing mir achieved primates three doses mg kg- lna antimir leading long lasting reversible decrease total plasma cholesterol without evidence lna associated toxicities histopathological changes study animals findings demonstrate utility systemically administered lna antimirs exploring mirna function rodents primates support potential compounds new class therapeutics disease-associated mirnas 
